These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 9405482

  • 1. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl.
    de Jong R, van Wijk A, Haataja L, Heisterkamp N, Groffen J.
    J Biol Chem; 1997 Dec 19; 272(51):32649-55. PubMed ID: 9405482
    [Abstract] [Full Text] [Related]

  • 2. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
    Salgia R, Pisick E, Sattler M, Li JL, Uemura N, Wong WK, Burky SA, Hirai H, Chen LB, Griffin JD.
    J Biol Chem; 1996 Oct 11; 271(41):25198-203. PubMed ID: 8810278
    [Abstract] [Full Text] [Related]

  • 3. Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1).
    Sattler M, Salgia R, Shrikhande G, Verma S, Uemura N, Law SF, Golemis EA, Griffin JD.
    J Biol Chem; 1997 May 30; 272(22):14320-6. PubMed ID: 9162067
    [Abstract] [Full Text] [Related]

  • 4. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
    Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD.
    Oncogene; 1996 Feb 15; 12(4):839-46. PubMed ID: 8632906
    [Abstract] [Full Text] [Related]

  • 5. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
    de Jong R, ten Hoeve J, Heisterkamp N, Groffen J.
    J Biol Chem; 1995 Sep 15; 270(37):21468-71. PubMed ID: 7545163
    [Abstract] [Full Text] [Related]

  • 6. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
    Uemura N, Salgia R, Li JL, Pisick E, Sattler M, Griffin JD.
    Leukemia; 1997 Mar 15; 11(3):376-85. PubMed ID: 9067577
    [Abstract] [Full Text] [Related]

  • 7. Tyrosine phosphorylation of murine Crkl.
    de Jong R, Haataja L, Voncken JW, Heisterkamp N, Groffen J.
    Oncogene; 1995 Oct 19; 11(8):1469-74. PubMed ID: 7478571
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
    Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW.
    Blood; 1994 Nov 01; 84(9):2912-8. PubMed ID: 7524758
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
    Seo S, Nakamoto T, Takeshita M, Lu J, Sato T, Suzuki T, Kamikubo Y, Ichikawa M, Noda M, Ogawa S, Honda H, Oda H, Kurokawa M.
    Cancer Sci; 2011 Dec 01; 102(12):2109-17. PubMed ID: 21848808
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
    ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J.
    Blood; 1994 Sep 15; 84(6):1731-6. PubMed ID: 7521685
    [Abstract] [Full Text] [Related]

  • 14. Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells.
    Astier A, Manié SN, Law SF, Canty T, Haghayghi N, Druker BJ, Salgia R, Golemis EA, Freedman AS.
    Leuk Lymphoma; 1997 Dec 15; 28(1-2):65-72. PubMed ID: 9498705
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
    de Jong R, ten Hoeve J, Heisterkamp N, Groffen J.
    Oncogene; 1997 Feb 06; 14(5):507-13. PubMed ID: 9053848
    [Abstract] [Full Text] [Related]

  • 16. Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells.
    Manié SN, Beck AR, Astier A, Law SF, Canty T, Hirai H, Druker BJ, Avraham H, Haghayeghi N, Sattler M, Salgia R, Griffin JD, Golemis EA, Freedman AS.
    J Biol Chem; 1997 Feb 14; 272(7):4230-6. PubMed ID: 9020138
    [Abstract] [Full Text] [Related]

  • 17. Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins.
    Barber DL, Mason JM, Fukazawa T, Reedquist KA, Druker BJ, Band H, D'Andrea AD.
    Blood; 1997 May 01; 89(9):3166-74. PubMed ID: 9129019
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.
    Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ.
    J Biol Chem; 1997 Jun 27; 272(26):16170-5. PubMed ID: 9195915
    [Abstract] [Full Text] [Related]

  • 20. BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
    Hemmeryckx B, Reichert A, Watanabe M, Kaartinen V, de Jong R, Pattengale PK, Groffen J, Heisterkamp N.
    Oncogene; 2002 May 09; 21(20):3225-31. PubMed ID: 12082638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.